Targeting the FAM49B-MDK-NCL pathway, particularly in combination with existing immune checkpoint inhibitors, holds promise as a new avenue for precision immunotherapy in CRC, ultimately improving survival outcomes for patients with metastatic disease. Here, MDK is linked to metastatic neoplasm.